<html xml:lang="en-us" lang="en-us" xmlns="http://www.w3.org/1999/xhtml" xmlns:epub="http://www.idpf.org/2007/ops"><head>
    <link rel="stylesheet" type="text/css" href="../../../../css/base.css" />
<link rel="stylesheet" type="text/css" href="../../../../css/kotobeeInteractive.css" />
<link rel="stylesheet" type="text/css" href="../../../../css/global.css" />
<link rel="stylesheet" type="text/css" href="../css/base.css" />
<link rel="stylesheet" type="text/css" href="../css/global.css" />
<link rel="stylesheet" type="text/css" href="../css/kotobeeInteractive.css" />

    <script type="text/javascript" src="../../../../js/kotobeeInteractive.js"></script>
<script type="text/javascript" src="../../../../js/global.js"></script>
<script type="text/javascript" src="../js/kotobeeInteractive.js"></script>
<script type="text/javascript" src="../js/global.js"></script>

    <title>Ketamine infusions</title>
    

<meta name="m-checksum" content="750995275" />
<meta charset="utf-8" />
 <meta name="kotobee-chapter" content="epubypzqs\EPUB\xhtml\ss8vps.xhtml" />
<meta name="kotobee-book" content="urn:uuid:7fcfad11-bf59-9bd2-4448-2a110d5910bc" />
</head>
<body>
<p><strong><em>Ketamine in palliative patients should only be used under the direction of a palliative care specialist. Speak to one before initiating ketamine</em></strong></p>

<p>Ketamine <em><sup>(non-PBS)</sup></em> is an option in patients with a terminal illness who have severe pain refractory to other treatments although the evidence is mixed and conflicting</p>

<p><strong>Indication: </strong>Pain (especially neuropathic pain) refractory to other analgesia</p>

<p><strong>Before starting</strong></p>

<ul>
	<li>Check blood pressure, heart rate, respiratory rate and conscious level</li>
	<li>Exclude contraindications</li>
	<li>If longer term use (&gt;weeks) is anticipated, ensure hepatotoxicity and urotoxicity are considered when obtaining consent and arranging monitoring</li>
	<li>Prescribe PRN haloperidol and PRN midazolam for hallucinations and anxiety respectively</li>
	<li>Continue to check blood pressure, heart and respiratory rate and conscious level three times daily</li>
</ul>

<p><strong>Subcutaneous administration regimen</strong></p>

<ul>
	<li>Commence 100mg via continuous SC infusion over 24 hours<br />
	(In a thin and elderly person, consider beginning at 50mg over 24 hours)</li>
	<li>PRN ketamine 25mg 4-hourly can be prescribed in addition to PRN opioids</li>
	<li>If inadequate analgesia is achieved, consider increasing the infusion rate by 100mg every 24-48 hours to a maximum dose of 500mg per day</li>
	<li>Continue to monitor blood pressure, heart rate, respiratory rate and conscious level</li>
</ul>

<p><strong>Oral administration regimen</strong></p>

<ul>
	<li>Ketamine can also be taken orally but dosing protocols vary widely</li>
	<li>Commence 10mg orally three times daily and 10mg PRN 4 hourly</li>
	<li>If inadequate analgesia is achieved, consider increasing in 10mg increments every 24-48 hours to a maximum dose of 100mg three times daily</li>
	<li>Continue to monitor blood pressure, heart rate, respiratory rate and conscious level</li>
</ul>

<p><strong>Stopping ketamine</strong></p>

<ul>
	<li>If significant side effects occur (especially sedation and reduced respiratory rate) then stop the ketamine</li>
	<li>If there has been no improvement in pain 24 hours after reaching the maximum dose, stop the ketamine (tapering is not required)</li>
	<li>If good analgesia occurs, consider gradually tapering the dose by similar increments and rate as the above titration</li>
	<li>If pain recurs, consider either an oral or subcut&#160;maintenance dose (discuss monitoring arrangements for hepatotoxicity and urotoxicity with a consultant) or another analgesic agent, e.g. methadone</li>
</ul>

<table>
	<tbody>
		<tr>
			<td><strong>Absolute contraindications</strong></td>
		</tr>
		<tr>
			<td>Previous serious reaction</td>
		</tr>
		<tr>
			<td>Recent or poorly controlled seizures</td>
		</tr>
		<tr>
			<td>Raised intracranial pressure</td>
		</tr>
		<tr>
			<td>Uncontrolled hypertension</td>
		</tr>
		<tr>
			<td><strong>Precautions</strong></td>
		</tr>
		<tr>
			<td>Brain metastases</td>
		</tr>
		<tr>
			<td>Possible raised ICP</td>
		</tr>
		<tr>
			<td>Previous strokes</td>
		</tr>
		<tr>
			<td>Severe cardiac failure</td>
		</tr>
		<tr>
			<td>Tachyarrhythmias</td>
		</tr>
		<tr>
			<td>History of glaucoma</td>
		</tr>
	</tbody>
</table>

<p>&#160;</p>

<table>
	<tbody>
		<tr>
			<td><strong>Adverse effects</strong></td>
		</tr>
		<tr>
			<td>Improved efficacy of other opioids resulting in opioid toxicity</td>
		</tr>
		<tr>
			<td>
			<p>Sympathomimetic effects</p>

			<ul>
				<li>Raised blood pressure</li>
				<li>Tachycardia</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td>
			<p>Psychomimetic effects</p>

			<ul>
				<li>Vivid dreams</li>
				<li>Hallucinations</li>
				<li>Agitation</li>
				<li>Sedation</li>
			</ul>
			</td>
		</tr>
		<tr>
			<td>Urotoxicity – suspect if recurrent UTI-like symptoms</td>
		</tr>
	</tbody>
</table>

<p>&#160;</p>

<p>Subcutaneous dosing and compatibilities:</p>

<ul>
	<li>5mg oral ≈ 5mg subcut</li>
	<li>Ketamine compatibilities are found in the <a class="link768" href="../../../raw/s7kfuf.xhtml">various compatibility tables</a></li>
</ul>

<p>&#160;</p>


</body></html>